TP53 deletion and relapsed disease at the time of transplant can independently predict progression in people with multiple myeloma treated with proteasome inhibitor and/or immunomodulatory drugs and auto-HCT, according to a study involving 145 individuals.

Investigators looked at outcomes in those with (n=34) and without (n=111) TP53 deletion. Among the results:

• 7 in every 10 TP53 deletion patients had relapsed disease at auto-HCT, vs 4 in every 10 in the group without such deletion.

• Median progression-free survival was 8 months for patients in the TP53 deletion group, vs 28 months in those without the deletion.

• Median overall survival was 21 months for patients in the TP53 deletion group, vs 56 months for those without the deletion.

• Patients with TP53 deletion had a more than 3-fold increased risk of earlier progression; those with relapsed disease at auto-HCT had twice the risk of such.

Citation: Gaballa S, Saliba R, Srour S, et al. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. [Published online ahead of print September 3, 2016]. Am J Hematol. doi:10.1002/ajh.24487.